The Life Sciences team advised EQRx through its launch and $200 million Series A Financing to create novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems. Leveraging advances in science and technology to bring treatments for life threatening and chronic diseases to people more efficiently and cost-effectively, EQRx intends to offer its therapies at dramatically lower prices compared to today’s innovative medicines.
EQRx committed to making innovative medicines at dramatically lower prices for the benefit of people and society. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
Goodwin has advised EQRx since its formation. The financing was led by Bill Collins and included Kingsley Taft, Mayan Katz, and Brett Jackson (financing). EQRx's business development activities are handled by Erini Svokos, Ian Longacre, and Cathy McCarty (IP).
For more details, read the press release and articles in CNBC, Endpoints News, Financial Times and The Wall Street Journal.